Expanding the Treatment of Calcified Lesions

[1]  R. Waksman,et al.  Reply to the letter to the editor "Impella device use in high-risk PCI". , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  R. Torguson,et al.  Adverse Events and Modes of Failure Related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[3]  R. Waksman,et al.  Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database. , 2019, EuroIntervention.

[4]  S. Bilazarian,et al.  Letter by Bilazarian et al. regarding the article, "Adverse events and modes of failure related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) database" by Khalid et al. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[5]  R. Waksman,et al.  Adverse Events Associated with the Use of Guide Extension Catheters during Percutaneous Coronary Intervention: Reports from the Manufacturer and User Facility Device Experience (MAUDE) database. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[6]  Deepak L. Bhatt,et al.  Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database , 2017 .

[7]  R. Waksman,et al.  Review: Stent fracture in the drug-eluting stent era. , 2016, Cardiovascular revascularization medicine : including molecular interventions.

[8]  R. Vogelzang,et al.  Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. , 2014, Journal of vascular and interventional radiology : JVIR.